TrialNeuro-oncology2018

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.

Benjamin M Ellingson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.